08:00 , Feb 13, 2012 |  BC Week In Review  |  Company News

AGI Therapeutics, Aravis Therapeutics deal

AGI said shareholders had tendered 54 million shares (80.2%) under Aravis' offer to acquire AGI for €10.7 million ($14 million). The offer remains open until Feb. 17 (see BioCentury, Jan. 16). AGI Therapeutics plc (ISE:A91;...
08:00 , Jan 16, 2012 |  BC Week In Review  |  Company News

AGI Therapeutics, Aravis Therapeutics deal

Aravis began its tender offer to acquire AGI Therapeutics for €10.7 million ($13.6 million) in cash. AGI's board unanimously recommended that AGI shareholders accept the offer. Aravis said the acquisition will provide a management team...
07:00 , Aug 1, 2011 |  BC Week In Review  |  Company News

AGI Therapeutics, Warner Chilcott deal

Warner Chilcott said it acquired a patent portfolio from AGI for about $300,000. The deal includes rights to an undisclosed compound for treating gastrointestinal conditions. Details were not disclosed. AGI Therapeutics plc (ISE:A9I; LSE:AGI), Dublin,...
08:00 , Nov 2, 2009 |  BC Week In Review  |  Company News

Questcor management update

Questcor Pharmaceuticals Inc. (NASDAQ:QCOR), Union City, Calif.   Business: Neurology, Autoimmune   Hired: David Young, a director, as CSO, formerly executive director and president of U.S. operations of AGI Therapeutics plc   ...
07:00 , Aug 24, 2009 |  BC Week In Review  |  Company News

AGI Therapeutics, TPG Capital deal

AGI Therapeutics regained full rights to AGI-010 after TPG Capital's Axcan Pharma Inc. unit and AGI Therapeutics mutually ended a 2006 deal to co-develop the compound in the U.S. and Canada to...
07:00 , Jul 6, 2009 |  BioCentury  |  Finance

2Q Approvals & Setbacks

2Q Approvals & Setbacks Selected second quarter product approvals. (A) Schering-Plough Corp. (NYSE:SGP) is merging with Merck & Co. Inc. (NYSE:MRK); (B) Wyeth is being acquired by Pfizer Inc. (NYSE:PFE) Company Approval Allergan Inc....
07:00 , May 18, 2009 |  BC Week In Review  |  Clinical News

Arverapamil: Development discontinued

AGI said it would discontinue development of Rezular for IBS-D after top-line data from the double-blind, international Phase III ARDIS-1 trial in 711 patients showed that Rezular missed the primary endpoint of patient reported adequate...
07:00 , May 18, 2009 |  BioCentury  |  Finance

Ebb & Flow

Just after reporting its first profitable quarter, respiratory specialist Cornerstone Therapeutics Inc. (NASDAQ:CRTX) decided to exchange half the company for the right to become the U.S. marketing arm of Italian drug company Chiesi Farmaceutici S.p.A. The...
01:26 , May 16, 2009 |  BC Extra  |  Top Story

AGI discontinues Rezular

AGI Therapeutics plc (ISE:A9I; LSE:AGI) closed down 23.5p (59%) to 16p on LSE and down EUR 0.32 (68%) to EUR 0.15 on ISE on Friday after discontinuing development of Rezular arverapamil for diarrhea-predominant irritable bowel...
07:00 , Apr 6, 2009 |  BC Week In Review  |  Clinical News

Arverapamil: Completed Phase III enrollment

AGI completed enrollment of 100 patients in the 1-year, open-label, international Phase III ARDIS-3 safety trial evaluating oral Rezular in patients. AGI Therapeutics plc (ISE:A9I; LSE:AGI), Dublin, Ireland   Product: Arverapamil (Rezular) (AGI-003)   Business: Gastrointestinal   Molecular...